Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNH2 | Q12809 | 2/20 | 0.51 |
| ▸ | FGFR1 | P11362 | 2/20 | 0.47 |
| ▸ | FGFR4 | P22455 | 1/20 | 0.47 |
| ▸ | KDR | P35968 | 1/20 | 0.47 |
| ▸ | FGFR3 | P22607 | 7/20 | 0.46 |
| ▸ | BCL6 | P41182 | 7/20 | 0.40 |
| ▸ | TNK2 | Q07912 | 1/20 | 0.40 |
| ▸ | PTK2 | Q05397 | 1/20 | 0.40 |
| ▸ | NCOR2 | Q9Y618 | 1/20 | 0.39 |
| ▸ | CDK1 | P06493 | 1/20 | 0.38 |
| ▸ | CDK4 | P11802 | 1/20 | 0.38 |
| ▸ | CCNB1 | P14635 | 1/20 | 0.38 |
| ▸ | CCND1 | P24385 | 1/20 | 0.38 |
| ▸ | CCNE1 | P24864 | 1/20 | 0.38 |
| ▸ | CDK2 | P24941 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17470065 | 0.95 | FGFR3 (0.52) | KCNH2FGFR1FGFR4KDRFGFR3 | |
| SCHEMBL17470064 | 0.93 | FGFR3 (0.52) | KCNH2FGFR1FGFR4KDRFGFR3 | |
| SCHEMBL17470147 | 0.93 | FGFR1 (0.52) | KCNH2FGFR1FGFR4KDRFGFR3 | |
| SCHEMBL17470057 | 0.90 | FGFR3 (0.48) | KCNH2FGFR1FGFR4KDRFGFR3 | |
| SCHEMBL17470095 | 0.90 | FGFR1 (0.54) | KCNH2FGFR1FGFR4KDRFGFR3 | |
| SCHEMBL17469990 | 0.89 | FGFR3 (0.45) | KCNH2FGFR1FGFR4KDRFGFR3 | |
| SCHEMBL16070226 | 0.89 | FGFR3 (0.51) | KCNH2FGFR1FGFR4KDRFGFR3 | |
| SCHEMBL17469987 | 0.88 | FGFR1 (0.45) | KCNH2FGFR1FGFR3BCL6 | |
| SCHEMBL19101594 | 0.87 | KCNH2 (0.46) | KCNH2FGFR1FGFR4KDRFGFR3 | |
| SCHEMBL17470202 | 0.85 | TNK2 (0.47) | FGFR1FGFR4KDRFGFR3BCL6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9701680-B2 | Pyrimidine and pyridine compounds and their usage | HUTCHISON MEDIPHARMA LIMITED (CN) | 2017-07-11 | — | — | US | disclosed |
| US-20160052926-A1 | NOVEL PYRIMIDINE AND PYRIDINE COMPOUNDS AND USAGE THEREOF | HUTCHISON MEDIPHARMA LIMITED (CN) | 2016-02-25 | — | — | US | disclosed |
| US-20160024021-A1 | NOVEL PYRIMIDINE AND PYRIDINE COMPOUNDS AND THEIR USAGE | HUTCHISON MEDIPHARMA LIMITED (CN) | 2016-01-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160052926-A1 | NOVEL PYRIMIDINE AND PYRIDINE COMPOUNDS AND USAGE THEREOF | FGFR3, FGFR1, FGFR4 | KCNH2 2589/4885FGFR1 2/4885FGFR4 3/4885 |
| US-20160024021-A1 | NOVEL PYRIMIDINE AND PYRIDINE COMPOUNDS AND THEIR USAGE | FGFR3, FGFR1, FGFR4 | KCNH2 2621/4885FGFR1 2/4885FGFR4 3/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.